Exciting news in the fight against prostate cancer! A cutting-edge trial has just been launched in the UK aiming to revolutionise treatment with fewer side-effects. Researchers are putting Aquablation therapy to the test, a state-of-the-art approach using robotics, AI, and real-time imaging to target the cancer while preserving quality of life. Unlike traditional surgery, which can lead to serious side-effects like infection, urinary issues, and erectile dysfunction, Aquablation seeks to minimise these risks.
Philip Charlesworth, a leading urological surgeon at the Royal Marsden, expresses high hopes for this trial, which is being backed by the National Institute for Health and Care Research. He explains that for men with prostate cancer confined to the prostate, the new approach could prove just as effective but with less harm. The technology allows medics to precisely identify and remove cancerous tissue while safeguarding nerves and muscles crucial for continence and sexual function.
The trial is making waves globally, with 280 patients set to participate. The Royal Marsden is the first European hospital to recruit a patient for this promising study, which spans seven countries. The therapy is already used in treating benign prostatic hyperplasia and could soon offer a powerful alternative for localised prostate cancer treatments.
This trial comes amidst debates on prostate cancer screening in the UK. The current recommendation does not support routine screening for most men, a decision that Health Secretary Wes Streeting finds surprising. Many experts argue that the current PSA test isn’t reliable enough as it could lead to unnecessary treatments. However, ongoing studies might pave the way for better testing methods.
With a growing focus on reducing treatment side-effects, Aquablation could be a game-changer. Keep an eye on this space for more updates on how this exciting trial develops, as it holds promise for a brighter future in prostate cancer care!